The DermaFlow technology was invented by Ilya Skoletsky, an experienced electronic engineer who was one of the pioneers of the Technology Incubator Programme, devised to provide financial and technical resources to inventors and entrepreneurs.
Ilya had the idea of creating a simple, scalable and cost-effective system for measuring peripheral blood flow. Up to this time, the technology, costs and manufacturing features were never suitable for routine and widespread utilization. Working in the Incubator gave Ilya the resources to produce the first prototype.
Irene Jaffe met Ilya at the Incubator and realized the future clinical and commercial potential of a non-invasive sensing of peripheral blood flow. She teamed up with Ilya and Jim Kleinburd to found DermaFlow. Together, the three have supervised the development of the technology to where it is today, establishing the monitoring of peripheral blood flow as the next vital sign.
The value of vital sign measurement in determining the patient’s state of health is at the core of diagnostic medicine. In particular, vital signs can give an indication of an acute medical problem, a means of quantifying the magnitude of the illness, as an indicator of chronic disease states and as a gauge of the progress of treatment.
The role of the microcirculation in the pathophysiology of disease states has long been recognized, as has been the need for non-invasive methods of measurements.
DermaFlow peripheral blood flow monitoring technology provides both clinician and consumer with the opportunity of user-friendly, non-invasive and accurate monitoring of the dermal microcirculation, and brings to the forefront the next vital sign in the assessment of both acute and chronic disease states.
What We've Achieved
Invented patented technology for routine non-invasive and sensitive measurement of peripheral circulation that is scalable
Developed prototype systems for in-vitro and in-vivo proof-of-concept trials
Conducted early hospital clinical trials in ICU, vascular and wound healing in Israel and the US
Presented trial data at medical conventions, subsequently published
Expedited technical development to improve and evolve hardware and create software
Implemented modular product strategy inclusive of standalone devices and embeddable modules as viable business models towards monetization both in consumer and clinical markets
Licensed first therapeutic technology to be used in conjunction with DermaFlow technology to create a dual functional health care wearable for consumers